You are here

Antimicrobial dermal matrices to promote infection free wound closure in DTU-DFUs.

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44DK137730-01
Agency Tracking Number: R44DK137730
Amount: $1,119,996.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 200
Solicitation Number: PA22-177
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-10-01
Award End Date (Contract End Date): 2025-09-30
Small Business Information
Brighton, MA 02135-1243
United States
DUNS: 079722830
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (617) 903-0678
Business Contact
Phone: (617) 903-0678
Research Institution

Project Summary/AbstractDFUs will affect more than 30% of diabetic patients within their lifetime and costs the US
healthcare system over $20 billion annually. Many DFUs fail to heal effectively and require
extensive medical intervention. Nearly 50% of DFUs worsen to “tunnel” into deep tissues
involving tendons and bones (DTU-DFUs). When this happens, DFUs are susceptible to severe
complications like infection, which significantly increases cost of treatment and the risk of lower
limb amputation and death.The current treatment for DTU-DFUs is expensive, time consuming, complicated, and
involves the sequential and cyclical application of multiple products. Antimicrobial management
is always the first step in wound care, as failure to keep a wound free of infection limits healing.
Despite the many antimicrobial products available, outcomes remain unsatisfactory.Gel4Med has developed G4Derm, a biosynthetic flowable wound care product designed
to address complex DTU-DFUs. G4Derm has already demonstrated efficacy and safety in
preclinical studies. The final product is a flowable scaffolding matrix provided as a shelf-stable,
ready, and easy-to-use syringe with an applicator tip. The flowable form factor allows G4Derm
to completely fill cavities of complex tunneling wounds. Once applied, the hydrogel resolves into
a scaffolding matrix with mammalian cell attachment sites to facility tissue regeneration. The
patented composition of G4Derm is uniquely and inherently antimicrobial – the gel disrupts
bacterial membranes on contact. In combination, these characteristics make G4Derm a highly
useful product to address the dire unmet need of DTU-DFUs.The goal of this proposal is to evaluate the clinical efficacy, safety, and feasibility of
G4Derm in an early-phase, pilot clinical study for patients with refractory DTU-DFUs. This
clinical evaluation is key to making G4Derm available to patients with DTU wounds. Gel4Med
will collect data on wound healing, tissue regeneration, quality of life, and risk of infection. After
the treatment period, patients will be able to participate in a 6-month follow-up period to assess
the risk of recurrence and durability of wound closure.The completion of this pilot clinical study is a key step to bringing G4Derm, which
combines enhanced wound healing with microbial management, to patients with treatment-
resistant DTU-DFUs and represents a paradigm shift in the treatment complex chronic wounds.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government